NEW MEMBER SIGN UP
  Display Name
 
  Email Address
 
  Password
 
  Password again
 
  Zip
 
Country
 
   

Close Window

Privacy Statement
BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
     
Community Login

What is this?
Biotechnology and Pharmaceutical ChannelMedical Device and Diagnostics ChannelClinical Research Channel Employers
 Post Job | Search Resumes | Login

NEWSLETTERS
Free Newsletters
Archive
My eNewsletters

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

COMMUNITY
Login
Become a Member
Discussion Forums
FAQ

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

  News | News By Subject | News by Disease News By Date | Search News
 Diseases - Melanoma
Genta Incorporated (GETA.OB) Initiates Phase 2 Study of Tesetaxel, the Leading Clinical-Stage Oral Taxane, in Patients with Advanced Melanoma   2/8/2010  More...
Vical Incorporated (VICL) Completes Enrollment in Allovectin-7(r) Phase 3 Trial for Metastatic Melanoma   1/28/2010  More...
Vical Incorporated (VICL) Announces Licensee's Approval of ONCEPT(TM) Therapeutic Melanoma Vaccine for Dogs   1/11/2010  More...
Pfizer Inc. (PFE) (JOBS) And Debiopharm Collaborate To Co-Develop Investigational Compound Tremelimumab (CP-675,206) In Advanced Melanoma   1/7/2010  More...
BioVex Announces Broadened Inclusion Criteria in Phase 3 Melanoma Study; OncoVEX to be Evaluated in First Line Patients and Those Previously Treated   1/6/2010  More...
Initial Phase 2 Results for Myriad Pharmaceuticals, Inc.' Azixa(TM) (MPC-6827) in Metastatic Melanoma   11/19/2009  More...
Abraxis BioScience, Inc. Release: ABRAXANE(R) Receives Orphan Drug Status for the Treatment of Pancreatic Cancer and Stage IIB-IV Melanoma   11/5/2009  More...
BioVex Announces Publication of Phase 2 Melanoma Results With OncoVEX (GM-CSF) in the Journal of Clinical Oncology   11/3/2009  More...
Genta Incorporated (GETA.OB) Announces Top-Line Results of AGENDA Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma, Trial Fails to Meet Primary Endpoint; Stock Down 70.0% at Market Close   10/30/2009  More...
Studies Show Early Promise of MannKind Corporation (MNKD)'s Cancer Immunotherapy Program in Melanoma, Prostate Cancer and Other Solid Malignancies   10/29/2009  More...
Myriad Pharmaceuticals, Inc.' Azixa(TM) is Efficacious in a Model of Human Brain Cancer and Its Activity is Additive With Avastin(R)   10/26/2009  More...
Melanoma Treatment Options One Step Closer, University of Alberta Study   10/21/2009  More...
Delcath Systems, Inc. (DCTH) Completes Phase III Study Enrollment   10/21/2009  More...
Threshold Pharmaceuticals, Inc. (THLD) Presents Interim Data From a Phase 1/2 Clinical Trial of TH-302 At Melanoma Conference   10/9/2009  More...
FDA Advisory Committee Recommends Approval of Schering-Plough Corporation (SGP)'s (JOBS) PEGINTRON(R) for the Adjuvant Treatment of Stage III Malignant Melanoma   10/5/2009  More...
FDA Finds "Subtantial" Toxicity with Schering-Plough Corporation (SGP)'s (JOBS) PegIntron Use   10/1/2009  More...
Oncolytics Biotech Inc. (ONC.TO) Announces Reovirus and Cisplatin Research Supports U.S. Phase 2 Metastatic Melanoma Trial   9/25/2009  More...
Oncolytics Biotech Inc. (ONC.TO) Announces Start of Enrolment in U.S. Phase 2 Melanoma Cancer Clinical Trial   9/24/2009  More...
Melanoma Patients Live Longer on Roche (RHHBY)'s (JOBS) Avastin   9/21/2009  More...
Hoag Presbyterian Memorial Hospital Release: Study Shows Cancer Vaccines Led to Long-Term Survival for Patients with Metastatic Melanoma and to Long Periods of Disease Control After Completion of Therapy   7/29/2009  More...
Delcath Systems, Inc. (DCTH) Provides Update on Progress; Patient Enrollment in Phase III Metastatic Melanoma Trial Now at 79 Conference Call to Discuss Second Quarter Results Today at 4:30 PM ET   7/28/2009  More...
NeoGenomics, Inc. (NGNM.OB) Enters into Strategic Supply Agreement with Abbott Laboratories (ABT) (JOBS) for Development of a Melanoma Cancer Test; Abbott Has Also Acquired 9.6% of NeoGenomics Common Stock for $4.8 Million   7/24/2009  More...
Thallion Pharmaceuticals Inc. Halts Trial Enrollment Over Dispute   7/8/2009  More...
Novel Epigenetic Markers Of Melanoma May Herald New Treatments For Patients, Yale University Study   7/1/2009  More...
Plexxikon Inc., Roche Holding AG (RHHBF.PK)'s (JOBS) Targeted Drug Shows Promise Against Melanoma   6/1/2009  More...
Vaccine Trains Killer Cells to Battle Melanoma, M. D. Anderson Cancer Center Study   6/1/2009  More...
BioVex To Announce Updated Survival Data From a Phase II Clinical Study of OncoVEX GM-CSF in Metastatic Melanoma at The 2009 American Society of Clinical Oncology Meeting   5/15/2009  More...
ZymoGenetics, Inc. (ZGEN) Reports Encouraging Preliminary Results from Phase 2 Study of IL-21 in Metastatic Melanoma Conducted by NCIC   5/13/2009  More...
AlphaVax, Inc. Announces Promising Results in Melanoma Studies   5/13/2009  More...
Vitamin D Supplements No Help Against Melanoma, Kaiser Permanente Study   5/8/2009  More...
Genta Incorporated (GNTA) Updates Late-Stage Progress of its Phase 3 Trial of Genasense(R) in Advanced Melanoma   4/29/2009  More...
BioAlliance Pharma Presents Results on Its New Biotherapy Plasmid AMEP(TM) for Metastatic Melanoma at the American Association for Cancer Research 100Th Annual Meeting in Denver, April 18 to 22, 2009   4/21/2009  More...
New Therapeutic Target For Melanoma Identified, Albany Medical College And Thomas Jefferson University Study   4/16/2009  More...
BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma   4/14/2009  More...
New Strategy Developed To Diagnose Melanoma, University of California, San Francisco (UCSF) Study   3/31/2009  More...
Data Safety Monitoring Board Unanimously Recommends Continuation of Delcath Systems, Inc. (DCTH) Phase III Clinical Trial for Inoperable Metastatic Melanoma   3/23/2009  More...
Adherex Technologies Inc. (ADH)'s Drug Could Make Melanoma More Vulnerable To Chemo, Duke University Study   3/9/2009  More...
Synta Pharmaceuticals (JOBS) Suspends Elesclomol SYMMETRYSM Trial in Metastatic Melanoma   2/27/2009  More...
TransMolecular, Inc. Receives Orphan Drug Designation for 131I-TM601 for the Treatment of Melanoma   12/22/2008  More...
Alnylam Pharmaceuticals (ALNY) Forms Collaboration with University of California, San Francisco (UCSF) to Investigate Therapeutic Silencing of Key Gene Implicated in Uveal Melanoma   12/10/2008  More...
Single Cancer Cell 'Poses Danger', University of Michigan Study   12/4/2008  More...
Genta Incorporated (GNTA) Release: Tesetaxel, a Leading Oral Taxane in Clinical Development, Receives FDA Designation as an Orphan Drug for Treatment of Patients with Advanced Melanoma   12/4/2008  More...
Provectus Pharmaceuticals Inc. Release: Enrollment in Provectus’ Phase 2 Melanoma Clinical Trial Reaches Halfway Point   11/25/2008  More...
Thallion Pharmaceuticals Inc. Initiates Enrollment in Phase II Metastatic Melanoma Trial   11/18/2008  More...
SciClone Pharmaceuticals, Inc. (SCLN) Reaches Agreement With FDA on Special Protocol Assessment for Phase 3 Thymalfasin Trial in Stage IV Melanoma   11/17/2008  More...
CuraGen Corporation (CRGN) Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma   11/3/2008  More...
Provectus Pharmaceuticals Inc. Adds Fifth Center to Phase 2 Clinical Trial of PV-10   10/31/2008  More...
T-Cell Infusion Therapy Boosts Melanoma Survival, French Researchers Say   10/23/2008  More...
Provectus Pharmaceuticals Inc. Announces First Peer-Reviewed Publication on PV-10 in "Melanoma Research"   10/14/2008  More...
Ludesi's 2D Gel Image Analysis Enabled Discovery of Potential Therapeutic Targets for Melanoma Tumors   10/14/2008  More...
Genta Incorporated (GNTA) Updates Progress of its Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma   10/6/2008  More...
Investigator Presents On Delcath Systems, Inc. (DCTH) Phase III Trial Experience   10/6/2008  More...
Provectus Pharmaceuticals Inc. Lead Investigator Professor John F. Thompson Presents At "Perspectives in Melanoma XII" Conference   10/2/2008  More...
Delcath Systems, Inc. (DCTH) Adds Providence Cancer Center to Phase III Trial   9/24/2008  More...
Variant Of Vitamin D Receptor Gene Linked To Melanoma Risk, University of Padova Study   9/22/2008  More...
Genta Incorporated (GNTA) Announces Independent Monitoring Board Recommends Completion of Accrual to Genasense(R) Phase 3 AGENDA Trial in Advanced Melanoma   9/15/2008  More...
Bristol-Myers Squibb Company (BMY) and Medarex, Inc. (MEDX) Release: Updated Survival Data from Three Phase 2 Ipilimumab Studies Showed Almost Half of Previously Treated Metastatic Melanoma Patients Alive Beyond One Year   9/15/2008  More...
CuraGen Corporation (CRGN) Completes Enrollment in Phase II Trial of CR011-vcMMAE in Metastatic Melanoma   9/11/2008  More...
Delcath Systems, Inc. (DCTH) Expands Phase III Trial for Metastatic Melanoma to Include Swedish Medical Center in Colorado   8/21/2008  More...
Widely Prescribed Anti-parasite Drug Targets Cancer-causing Protein, New York University Cancer Institute and the Ronald O. Perelman Department of Dermatology Study   8/13/2008  More...
National Cancer Institute Starts Enrolment in Phase 2 Systemic Melanoma Clinical Trial with REOLYSIN(R)   8/12/2008  More...
GammaCan International, Inc. (GCAN.OB) Release: VitiGam(TM) Inhibits Melanoma Growth in a Dose Dependent Manner   8/11/2008  More...
Widely Prescribed Anti-parasite Drug Targets Cancer-causing Protein, New York University Cancer Institute and Ronald O. Perelman Department of Dermatology Research   8/7/2008  More...
Electro-Optical Sciences, Inc. Completes Patient Accrual in MelaFind(R) Pivotal Trial for Early Melanoma Detection   8/4/2008  More...
Protein Gives Doctors New Tool to Detect Melanoma in University of Rochester Study   7/24/2008  More...
Delcath Systems, Inc. (DCTH) Expands Phase III Trial for Metastatic Melanoma to Florida   7/24/2008  More...
PhiloGene, Inc. Announces that VEGFbTM has been Granted Orphan Drug Designation by the FDA for the Treatment of Advanced Melanoma   7/22/2008  More...
Provectus Pharmaceuticals Inc. Adds M. D. Anderson Cancer Center as First U.S. Center to Phase 2 Clinical Trial of PV-10   7/21/2008  More...
Provectus Pharmaceuticals Inc.'s Lead Investigator for Phase 2 Melanoma Study to Address the Inaugural Sydney Cancer Conference 2008   7/17/2008  More...
Schering-Plough Corporation (SGP)'s (JOBS) Pegintron Cuts Melanoma Return Risk in Phase 3 Study   7/11/2008  More...
Provectus Pharmaceuticals Inc. Release: First Twenty-Five Percent of Subjects in Phase 2 Melanoma Clinical Trial Treated   7/7/2008  More...
Journal of Clinical Oncology Publishes Bayer HealthCare Pharmaceuticals (BAY)' Leukine(R) Study Demonstrating Positive Survival Outcomes in Patients with High-Risk Melanoma   7/1/2008  More...
Hana Biosciences, Inc. (HNAB) Receives U.S. Orphan Drug Designation for Marqibo for the Treatment of Metastatic Uveal Melanoma   6/30/2008  More...
Painkillers Don't Protect Against Melanoma, Kaiser Permanente Northern California Research Finds   6/25/2008  More...
Genta Incorporated (GNTA) Updates Progress of its Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma Clinical Study on Track to Complete Accrual in Fourth Quarter 2008   6/24/2008  More...
Delcath Systems, Inc. (DCTH) Expands Multi-Center Phase III Trial for Metastatic Melanoma   6/24/2008  More...
University of Utah Melanoma Study: Genetic Test Determines Those at High-Risk for Deadly Cancer   6/23/2008  More...
Delcath Systems, Inc. (DCTH) Adds Atlantic Health to Phase III Trial for Metastatic Melanoma   6/19/2008  More...
Pain Therapeutics (PTIE) Encouraged by Results of Melanoma Clinical Study   6/16/2008  More...
Australia and New Zealand Melanoma Trials Group (ANZMTG) and Provectus Pharmaceuticals Inc. Release: Industry Supports International Research on New Melanoma Treatments   6/13/2008  More...
Novel Targeted Therapy Reduces Chemoresistance In Mouse Model Of Melanoma, University Medical Center Göttingen Study   6/11/2008  More...
CuraGen Corporation (CRGN) Announces Expansion of CR011-vcMMAE Phase II Trial in Melanoma   6/11/2008  More...
Neoprobe Corporation (NEOP) Commences Lymphoseek Phase 3 Trial   6/9/2008  More...
Bayer HealthCare Pharmaceuticals (BAY) Release: Study Supports Possible Use of Leukine(R) as a Potential Adjuvant Therapy for High-Risk Melanoma Patients - Phase II Data Indicate Overall and Disease-Free Survival   6/6/2008  More...
Delcath Systems, Inc. (DCTH) Adds the Cancer Center of Albany Medical Center to Phase III Trial for Metastatic Melanoma   6/4/2008  More...
GammaCan International, Inc. (GCAN.OB) Executes Supply Agreement with Bio Products Laboratory to Manufacture VitiGam(TM) for the Treatment of Melanoma for Clinical Testing and Commercial Sale   6/4/2008  More...
Medarex, Inc. (MEDX) Shares Fall Monday On Concerns Over Late-Stage Melanoma Drug Candidate Ipilimumab   6/3/2008  More...
Delcath Systems, Inc. (DCTH) Expands Phase III Trial for Metastatic Melanoma to Include St. Luke's Hospital & Health Network Cancer Center   6/3/2008  More...
ANTISENSE PHARMA GmbH Release: Anti-TGF-Beta Antisense AP 12009 Shows Very Good Safety and Tolerability in Systemic Treatment of Pancreatic Carcinoma, Malignant Melanoma and Colorectal Carcinoma   6/3/2008  More...
Abnormalities In Gene For Melanoma Found, Oregon Health & Science University (OHSU) Study   6/2/2008  More...
Hana Biosciences, Inc. (HNAB)' Phase 2 Clinical Trial of Marqibo for Metastatic Uveal Melanoma Meets Clinical Response Criteria to Advance to Full Enrollment   6/2/2008  More...
BioVex Reports Positive Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting   6/2/2008  More...
Medarex, Inc. (MEDX)'s Ipilimumab Plus Chemotherapy is Associated with Prolonged Survival and Increased Disease Control Rates in Patients with Advanced Melanoma; Updated Clinical Phase 2 Data Presented at American Society of Clinical Oncology Annual Meeting   6/2/2008  More...
CuraGen Corporation (CRGN) Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity Of CR011-Vcmmae In Metastatic Melanoma - Data Presented At The 2008 American Society of Clinical Oncology Annual Meeting - - Conference Call To Be Hosted Wednesday, June 4 At 9:00 A.M. EDT To Discuss Results   6/2/2008  More...
Bristol-Myers Squibb Company (BMY), Medarex, Inc. (MEDX) Release: New Ipilimumab Survival Data in Patients with Metastatic Melanoma Presented at American Society of Clinical Oncology Annual Meeting   6/2/2008  More...
Adherex Technologies Inc. (ADH) Announces Updated ADH-1 Chemotherapy Combination Data in Melanoma   6/2/2008  More...
TransMolecular, Inc. Reports Positive Results from Phase 1 Trial of 131Iodine-TM601 in Metastatic Melanoma   6/2/2008  More...
Genta Incorporated (GNTA) Genasense(R) Chemotherapy Program Yields High Response Rate in Patients with Stage 4 Melanoma   5/30/2008  More...
TransMolecular, Inc. Initiates Phase 1 Clinical Trial for Unlabeled TM601 in Recurrent Malignant Glioma   5/30/2008  More...
GlaxoSmithKline (GSK) and Synta Pharmaceuticals Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma   5/20/2008  More...
Skin-Tone Gene Could Predict Cancer Risk, Queensland Institute of Medical Research Study   5/19/2008  More...
Novel Enzyme Inhibitor Paves Way For New Cancer Drug: Agent Proves Effective Against Melanoma Cells, The Wistar Institute Study   5/19/2008  More...
Adherex Technologies Inc. (ADH) Announces American Society of Clinical Oncology Abstract of ADH-1 in Melanoma   5/19/2008  More...
Penn State University Scientists Identify Interacting Proteins Key To Melanoma Development, Treatment   5/6/2008  More...
Bristol-Myers Squibb Company (BMY), Medarex, Inc. (MEDX) Cancer Drug Hits Delay   4/28/2008  More...
Delcath Systems, Inc. (DCTH) Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center   4/28/2008  More...
Melanoma's Site May Determine Survival; Study Shows Neck, Scalp Melanoma Have Worst Survival Outcomes   4/22/2008  More...
BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma   4/22/2008  More...
First Targeted Therapy To Produce Remission Of Metastatic Melanoma, Dana-Farber Cancer Institute Research   4/21/2008  More...
Report Describes First Targeted Therapy To Produce Remission Of Metastatic Melanoma, Dana-Farber Cancer Institute Study   4/18/2008  More...
Oncolytics Biotech Inc. (ONC.TO) Announces Gene Therapy Publication on Reovirus Treatment for Melanoma   4/18/2008  More...
Sunesis Pharmaceuticals, Inc. (SNSS) Reports Data from Nonclinical Studies of SNS-032   4/16/2008  More...
Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma   4/15/2008  More...
New Study Shows KGK Synergize's Dermytol Produces Pronounced Decrease In Malignant Melanoma Tumor Volume   4/7/2008  More...
Pfizer Inc. (PFE) Announces Discontinuation of Phase III Clinical Trial for Patients with Advanced Melanoma   4/2/2008  More...
DSMB Supports Continuation of Genta Incorporated (GNTA) Phase 3 AGENDA Trial of Genasense(R) in Advanced Melanoma   3/31/2008  More...
Adherex Technologies Inc. (ADH) to Present ADH-1 Phase I/II Melanoma Trial Data at the 2008 Annual Meeting of the American Society of Clinical Oncology   3/20/2008  More...
Huntsman Cancer Institute Release: Allovectin-7(R) May Offer Patients a New Option for Advanced Melanoma   3/13/2008  More...
Inovio Biomedical Corporation's Electroporation Delivery Technology Demonstrates Safety and Positive Clinical Responses with Melanoma DNA Immunotherapy   3/11/2008  More...
EpiCept Corporation (EPCT) Earns Milestone Payment Due to Progress in Phase II Trial for Azixa(TM) in Melanoma Metastases   3/6/2008  More...
GammaCan International, Inc. (GCAN.OB) Announces Positive Testing Results in the Development of VitiGam(TM) for the Treatment of Melanoma   3/6/2008  More...
Ichor Medical Systems, Inc. Melanoma Vaccine Clinical Trial Moves to Highest Dose Level   3/4/2008  More...
Adherex Technologies Inc. (ADH) Receives Orphan Drug Designation for ADH-1 in Melanoma   2/22/2008  More...
Antisoma PLC (ASM.L) Starts Phase I Clinical Trial of AS1409 in Renal Cancer and Melanoma   2/21/2008  More...
Antigenics Inc. (New York) (AGEN) Cancer Vaccine Study Shows Mixed Results   2/20/2008  More...
Marshall Edwards, Inc. (NVGN)'s Triphendiol Gets Additional Orphan Drug Status   2/19/2008  More...
Researchers at The Cancer Center at Hackensack University Medical Center Participate in Study to Treat Advanced Melanoma   2/19/2008  More...
Howard Hughes Medical Institute Researchers Uncover Protein That Stops Melanoma Growth   2/8/2008  More...
Tysabri May Be Linked to Melanoma   2/7/2008  More...
Schering-Plough Corporation (SGP)'s Peg-IFN Gets FDA Priority Review Status   1/31/2008  More...
GlaxoSmithKline (GSK), Synta Pharmaceuticals Skin Cancer Drug Gets Orphan Status   1/28/2008  More...
Adherex Technologies Inc. (ADH) Announces Phase IIb Expansion of ADH-1 Combination Study in Melanoma   1/18/2008  More...
Vical Incorporated (VICL) Receives Payment from AnGes MG Inc. for Allovectin-7(R) Phase 3 Pivotal Trial   1/17/2008  More...
Electro-Optical Sciences, Inc. Announces MelaFind(R) Development Update   1/9/2008  More...
UIC Studies New Treatment for Advanced Melanoma   1/9/2008  More...
The Angeles Clinic and Research Institute Initiates Global Phase 3 Clinical Trial for New Melanoma Drug   1/7/2008  More...
AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma   1/3/2008  More...
IDM Pharma, Inc. (IDMI) Says Sanofi-Aventis (France) (SASY.PA) to End Venture, Sees Jobs Losses   12/31/2007  More...
University Hospitals Researchers Initiate Gene Therapy Trial in Patients with Advanced Skin Cancer   12/26/2007  More...
FDA Extends Review Period for Correction of Genasense Data- Genta Incorporated (GNTA)   12/21/2007  More...
Array BioPharma, Inc. (ARRY) Says AstraZeneca PLC (AZN) Not Taking AZD6244 to Phase III   12/20/2007  More...
DermTech International Is Issued U.S. Patent for the Early Detection, Staging and Monitoring of Melanoma   12/19/2007  More...
ZymoGenetics, Inc. (ZGEN) Begins Phase 2 Clinical Trial of IL-21 in Melanoma   12/18/2007  More...
ImClone Systems Incorporated (IMCL): Phase II Study of IMC-1121B for Advanced Malignant Melanoma Commences Patient Enrollment   12/13/2007  More...
Mixed Results from Bristol-Myers Squibb Company (BMY) (Jobs) and Medarex, Inc. (MEDX) Melanoma Trials   12/11/2007  More...
Specialists at Moores University of California, San Diego (UCSD) Cancer Center Evaluate New Option for Treating Advanced Melanoma   12/11/2007  More...
Bristol-Myers Squibb Company (BMY) and Medarex, Inc. (MEDX) Top-Line Data Available from Three Ipilimumab Pivotal Trials in Patients with Advanced Metastatic Melanoma   12/11/2007  More...
AVAX Technologies, Inc. (AVXT) Announces Successful Completion of Phase I / II Study of MVax(R) in Patients with Stage 3 and 4 Melanoma   12/11/2007  More...
John Wayne Cancer Institute: Allovectin-7® May Offer Patients a New Option for Advanced Melanoma   12/5/2007  More...
University of Michigan: Cancer Drug Works by Overactivating Cancer Gene; Melanoma Tumors Carry Enemy Within, Suggesting New Treatment Strategy   11/26/2007  More...
Hana Biosciences, Inc. (HNAB) Initiates Marqibo Phase 2 Clinical Trial   11/21/2007  More...
Cancer Drug Works by Overactivating Cancer Gene, University of Michigan Health System Study   11/20/2007  More...
AVAX Technologies, Inc. (AVXT) Announces the Initiation of Its Phase III Registration Trial of M-Vax(R) in Metastatic Melanoma   11/13/2007  More...
Synta Pharmaceuticals Reaches Agreement on Special Protocol Assessment and Initiates SYMMETRY Trial - a Pivotal Phase 3 Clinical Trial of Elesclomol in Metastatic Melanoma   11/12/2007  More...
Genta Incorporated (GNTA) Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium   11/8/2007  More...
IDM Pharma, Inc. (IDMI) Announces Updated Phase 2 UVIDEM(R) Results Showing Durable Disease Control and Tolerability in Advanced Melanoma Patients   11/2/2007  More...
M. D. Anderson Cancer Center Allovectin-7(R) May Offer Patients a New Option for Advanced Melanoma   11/1/2007  More...
Society for Melanoma Research Genes Unlock New Treatments for Deadly Melanoma   10/26/2007  More...
CuraGen Corporation (CRGN) Announces Presentation of Phase I Dose-Escalation Results on CR011   10/25/2007  More...
Genta Incorporated (GNTA) Genasense(R) Data in Patients with Advanced Melanoma to be Featured at 4th International Melanoma Congress   10/24/2007  More...
Allovectin-7(R) May Offer Patients a New Option for Advanced Melanoma, University of Arkansas for Medical Sciences Study   10/17/2007  More...
Southeastern Medical Oncology Center: Allovectin-7(R) May Offer Patients a New Option for Advanced Melanoma   10/10/2007  More...
Drug Study Seeks Those with Advanced Skin Cancer   10/1/2007  More...
GammaCan International, Inc. (GCAN.OB) Enters into Vitiligo Plasma Supply Agreement with DCI Biologicals   10/1/2007  More...
New Type of Drug Shows Promise in Attacking Melanoma in An Innovative Way   9/26/2007  More...
Lucid Release: Large Blinded Clinical Study Achieves High Accuracy for the Diagnosis of Melanoma Using In Vivo Confocal Microscopy   9/18/2007  More...
Oncolytics Biotech Inc. (ONC.TO) Release: Reovirus Infection of Melanoma Cells Generates Anti-Tumour Immunity   9/12/2007  More...
St. Luke's Hospital & Health Network: Allovectin-7(R) May Offer Patients a New Option for Advanced Melanoma   9/10/2007  More...
Neoprobe Corporation (NEOP) Provides Updated Phase 2 Clinical Data for Lymphoseek®   9/10/2007  More...
Melanoma Drug Revs Immune Cells But Cancer Cells Ignore It, Ohio State University Study   9/6/2007  More...
Genta Incorporated (GNTA) Release: Genasense(R) Data in Melanoma to be Presented   9/5/2007  More...
Provectus Pharmaceuticals Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma   9/5/2007  More...
Cyplasin Biomedical Ltd. (CYPL.OB) Release: Cyplasin-SC(TM) Kills Melanoma Cells, Even Derived from Different Patients but Leaves Normal Human Cells Unharmed   9/5/2007  More...
Advanced Life Sciences Holdings, Inc. (ADLS) Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma   8/28/2007  More...
Capitol Comprehensive Cancer Care Clinic: Allovectin-7® May Offer Patients a New Option for Advanced Melanoma   8/27/2007  More...
Genta Incorporated (GNTA) Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma   8/21/2007  More...
Comprehensive Blood and Cancer Center: Allovectin-7® May Offer Patients a New Option for Advanced Melanoma   8/20/2007  More...
GammaCan International, Inc. (GCAN.OB) Receives FDA Orphan Drug Designation for Lead Product VitiGam(TM) for Stage IIB to Stage IV Melanoma   8/7/2007  More...
European Medicines Evaluation Agency Indicates that Genta Incorporated (GNTA)'s Genasense(R) Approval in Melanoma Will Require Confirmatory Clinical Trial   7/20/2007  More...
Moles 'Good Indicator to Ageing', 'Skin Cancer Risk'   7/12/2007  More...
Delcath Systems, Inc. (DCTH) Expands Phase II Multi-Histology Clinical Trial   6/26/2007  More...
Neoprobe Corporation (NEOP) Phase 2 Lymphoseek Trial Meets Primary Endpoint   6/20/2007  More...
New Blood Test Detects Likelihood of Melanoma   6/14/2007  More...
IDM Pharma, Inc. (IDMI) Presents Preliminary Results from Phase II UVIDEM(R) Melanoma Vaccine Clinical Trial   6/5/2007  More...
Medarex, Inc. (MEDX) and Bristol-Myers Squibb Company (BMY) Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab   6/5/2007  More...
SciClone Pharmaceuticals, Inc. (SCLN) and Sigma-Tau Pharmaceuticals Report Thymalfasin Meets Primary Endpoint in Phase 2 Malignant Melanoma Trial   6/4/2007  More...
KOSAN Biosciences, Inc. (KOSN) Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at American Society of Clinical Oncology   6/4/2007  More...
Hana Biosciences, Inc. (HNAB) Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting   6/4/2007  More...
SciClone Pharmaceuticals, Inc. (SCLN)'s SCV-07 Inhibits Melanoma Tumor Growth in Animal Model Study   6/4/2007  More...
Inovio Biomedical Corporation (INO)'s DNA Delivery Technology Shows Safety and Enhances Gene Expression & Tumor Responses in Interim Melanoma Clinical Study Results   5/24/2007  More...
Synta Pharmaceuticals Oncology Candidate STA-4783 Clinical Trial Results to Be Presented at the American Society of Clinical Oncology Annual Meeting   5/23/2007  More...
Nanocomposite Labeled Cancer Cells Can be Targeted and Destroyed Using Lasers, Roswell Park Cancer Institute and University of Michigan Study   5/21/2007  More...
Morphotek Inc. Signs Development and Clinical Supply Agreement with CMC Biopharmaceuticals A/S for Therapeutic Antibody to Treat Melanoma   5/21/2007  More...
Provectus Pharmaceuticals Inc. Releases Video of Provecta(TM) in Action on Human Patient   5/21/2007  More...
U.S. National Cancer Institute Files for Phase 2 Systemic Melanoma Clinical Trial with REOLYSIN(R)   5/14/2007  More...
FDA Approves Phase I Clinical Trial Using Ichor Medical Systems, Inc.'s TriGrid System and DNA Vaccine for Melanoma Developed at Sloan-Kettering   5/14/2007  More...
Uveal Melanoma Patients at Higher Risk for Colon Cancer   5/9/2007  More...
Stanford University School of Medicine(Jobs) Researchers Identify Immune Dysfunction in Melanoma Patients   5/8/2007  More...
Viragen, Inc. (VRA) Multiferon(R) Shows Potent Activity in Preventing the Progression of Malignant Melanoma; Study to be Published   5/8/2007  More...
SciClone Pharmaceuticals, Inc. (SCLN) Announces ZADAXIN and SCV-07 Abstracts Accepted at American Society of Clinical Oncology   4/27/2007  More...